Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia

  • Fleischmann R
  • Kerr B
  • Yeh L
 et al. 
  • 26

    Readers

    Mendeley users who have this article in their library.
  • 17

    Citations

    Citations of this article.

Abstract

OBJECTIVE: The aim of this study was to evaluate the pharmacodynamics (PDs), pharmacokinetics (PKs) and safety of lesinurad (selective uric acid reabsorption inhibitor) in combination with febuxostat (xanthine oxidase inhibitor) in patients with gout. METHODS: This study was a phase IB, multicentre, open-label, multiple-dose study of gout patients with serum uric acid (sUA) >8 mg/dl following washout of urate-lowering therapy with colchicine flare prophylaxis. Febuxostat 40 or 80 mg/day was administered on days 1-21, lesinurad 400 mg/day was added on days 8-14 and then lesinurad was increased to 600 mg/day on days 15-21. sUA, urine uric acid and PK profiles were evaluated at the end of each week. Safety was assessed by adverse events, laboratory tests and physical examinations. RESULTS: Initial treatment with febuxostat 40 or 80 mg/day monotherapy resulted in 67% and 56% of subjects, respectively, achieving a sUA level

Author-supplied keywords

  • Drug-drug interaction
  • Febuxostat
  • Gout
  • Lesinurad
  • Pharmacodynamic
  • Pharmacokinetic
  • Selective uric acid reabsorption inhibitor
  • Xanthine oxidase inhibitor

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Roy Fleischmann

  • Bradley Kerr

  • Li Tain Yeh

  • Matt Suster

  • Zancong Shen

  • Elizabeth Polvent

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free